a study of rindopepimut/gm-csf in patients with relapsed egfrviii-positive glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma

Summary: the purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as cdx-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed egfrviii positive glioblastoma.

this phase ii study will enroll patients into three groups. group 1 are patients who have never been treated with bevacizumab. these patients will be randomly assigned to receive either rindopepimut/gm-csf or klh, each along with bevacizumab. treatment assignment for group 1 will be blinded. group 2 and group 2c patients are those who are refractory to bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or within 2 months of discontinuing bevacizumab). these patients will all receive rindopepimut/gm-csf along with bevacizumab. patients will be treated until disease progression or intolerance and all patients will be followed for survival. patients may be treated with other therapies that are not part of the study after discontinuing treatment with the study vaccine.

Eligibility criteria:
inclusion criteria: among other criteria, patients must meet the following conditions to be eligible for the study: 1. age ≥18 years of age. 2. histologic diagnosis of glioblastoma (who grade iv). 3. documented egfrvlll positive tumor status (central lab confirmation). 4. first or second relapse of de novo glioblastoma or first diagnosis or first relapse of secondary glioblastoma. 5. previous treatment must include surgery, conventional radiation therapy and temozolomide (tmz). 6. screening mri must be obtained at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy. 7. kps of ≥ 70%. 8. if applicable, systemic corticosteroid therapy must be at a dose of ≤ 4 mg of dexamethasone or equivalent per day during the week prior to day 1. 9. evaluable disease in groups 1 and 2; measurable disease in group 2c 10. life expectancy \> 12 weeks. 11. patients in group 2 and 2c must have had disease progression while receiving bevacizumab or within 2 months of treatment with bevacizumab. exclusion criteria: among other criteria, patients who meet the following conditions are not eligible for the study: 1. subjects unable to undergo an mri with contrast. 2. history, presence, or suspicion of metastatic disease 3. prior receipt of vaccination against egfrviii. 4. any known contraindications to receipt of study drugs, including known allergy or hypersensitivity to keyhole limpet hemocyanin (klh), gm-csf (sargramostim; leukine®), polysorbate 80 or yeast derived products, or a history of anaphylactic reactions to shellfish proteins. 5. use of non-protein based investigational therapy within 14 days prior to day 1 or use of antibody-based investigational therapy within 28 days prior to day 1. 6. clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment 7. evidence of recent hemorrhage on screening mri of the brain 8. evidence of current drug or alcohol abuse. 9. patients in group 1 must not have received prior treatment with bevacizumab.

Keywords: egfrviii glioblastoma rindopepimut cdx-110 small cell giant cell brain cancer brain tumor gliosarcoma oligodendroglial radiotherapy chemoradiation tumor bevacizumab relapsed returned recurrent egfr variant iii